Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Jennifer N. Saultz, Manoj Rai, Andy Kaempf, Sanjog Bastola, Hyun Cho, Nicola Long, Curtis A. Lachowiez, Gabrielle Meyers, Jessica T. Leonard, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner

Blood (2024) 144 (Supplement 1): 2859.

https://doi.org/10.1182/blood-2024-211860

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Somya Khare, Rachel J. Cook, Amrita Desai, Arpita Gandhi, Kelli Goslee, Brandon Hayes-Lattin, Curtis A Lachowiez, Jessica T. Leonard, Richard T. Maziarz, Gabrielle Meyers, Laura F. Newell, Jennifer N. Saultz, Ronan T. Swords, Elie Traer, Eneida R Nemecek

Blood (2024) 144 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2024-209407

Published: 2024

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2024-203361

Published: 2024

Journal Articles

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2024-208505

Published: 2024

Journal Articles

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Vishvaas I Ravikumar, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Mael Heiblig, Joshua F Zeidner, Daniel A Pollyea, Curtis A Lachowiez

Blood (2024) 144 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2024-201231

Published: 2024

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Uma Borate, Andy Kaempf, Jessica Minnier, Shikha Misra, Shaun Goodyear, Gabrielle Meyers, Jennifer N. Saultz, Elie Traer, Ronan Swords, Rachel J. Cook, Sammantha Avaylon, Melissa Mackey, Brianna Norris, Roland B. Walter

Blood (2021) 138 (Supplement 1): 1269.

https://doi.org/10.1182/blood-2021-152791

Published: 2021

Journal Articles

Success and Satisfaction with Virtual Hematology Curriculum Implemented in Response to COVID-19

Ali Noel Gunesch, Kristen McClellan, Gabrielle Meyers, Evan Shereck

Blood (2021) 138 (Supplement 1): 2970.

https://doi.org/10.1182/blood-2021-153891

Published: 2021

Journal Articles

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Jennifer N Saultz, DO, Kaycee Moshofsky, BS, Andy Kaempf, MS, Guang Fan, MD PhD, Gabrielle Meyers, Rachel J. Cook, MD, Richard T. Maziarz, MD, Peggy Appel, Francisco Tria, MD, Staci Williamson, MS

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-142048

Published: 2020

Journal Articles

Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single Institution

Weiwei Wang, PhD, Gabrielle Meyers, MD, Haibo Li, Ying Wang, Lisong Shen, MD PhD, Guang Fan, MD PhD

Blood (2019) 134 (Supplement_1): 948.

https://doi.org/10.1182/blood-2019-124896

Published: 2019

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Laura F. Newell, MD, Rebekah Knight, Kelsea Shoop, Sara Murray, Rogelyn Kwock, NP, Carol Jacoby, NP, Susan Slater, NP, Bryon Allen, NP, Brad Cota, MBA, Peggy Appel, Rachel J. Cook, MD, Richard T. Maziarz, MD, Gabrielle Meyers, MD

Blood (2018) 132 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2018-99-120342

Published: 2018

Journal Articles

Healthcare Consumption Amongst Older Patients with High Risk AML Treated with Hypomethylating Agents Is Similar to That of Patients Receiving Induction Chemotherapy

Curtis A Lachowiez, MD, Matthew Kearney, MD, Gabrielle Meyers, MD, Rachel J. Cook, MD

Blood (2017) 130 (Supplement 1): 2155.

https://doi.org/10.1182/blood.V130.Suppl_1.2155.2155

Published: 2017

Journal Articles

Identifying Unexpected Inherited Marrow Failure Syndromes in Adults Presenting with Aplastic Anemia, MDS or Solid Tumors

Curtis Lachowiez, MD, Gabrielle Meyers, MD

Blood (2016) 128 (22): 5071.

https://doi.org/10.1182/blood.V128.22.5071.5071

Published: 2016

Journal Articles

Elevated Placental Growth Factor Levels after Allogeneic Hematopoietic Cell Transplantation: Clinical and Peripheral Blood Mononuclear Cell Receptor Expression Correlates

Laura Newell, MD, Gabrielle Meyers, MD, Shernan G. Holtan, MD

Blood (2014) 124 (21): 5870.

https://doi.org/10.1182/blood.V124.21.5870.5870

Published: 2014

Journal Articles

The Contribution of Toll-like Receptor (TLR) Pathway Hyper-Reactivity to Clonal Selection in Secondary MDS and AML

Laura F. Newell, MD, R. K. Rathbun, Michael R Garbati, PhD, Kim-Hien T. Dao, DO,PhD, Shernan G. Holtan, MD, Rachel J Cook, MD MS, Gabrielle Meyers, MD, Grover C. Bagby, MD MACP

Blood (2014) 124 (21): 4621.

https://doi.org/10.1182/blood.V124.21.4621.4621

Published: 2014

Journal Articles

Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation

Shernan G. Holtan, MD, Michael R. Verneris, MD, Kirk R. Schultz, MD, Laura Newell, MD, Gabrielle Meyers, MD, Fiona C. He, MD, Todd E. DeFor, MS, Margaret L. MacMillan, MD, Sarah A. Cooley, MD MS, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 2489.

https://doi.org/10.1182/blood.V124.21.2489.2489

Published: 2014

Journal Articles

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Tibor Kovacsovics, Byung Park, Brandon Hayes-Lattin, Jose F. Leis, Peter T. Curtin, Gabrielle Meyers, Elliot Epner, Richard T. Maziarz

Blood (2007) 110 (11): 1988.

https://doi.org/10.1182/blood.V110.11.1988.1988

Published: 2007

NARROW

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Success and Satisfaction with Virtual Hematology Curriculum Implemented in Response to COVID-19

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single Institution

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Healthcare Consumption Amongst Older Patients with High Risk AML Treated with Hypomethylating Agents Is Similar to That of Patients Receiving Induction Chemotherapy

Identifying Unexpected Inherited Marrow Failure Syndromes in Adults Presenting with Aplastic Anemia, MDS or Solid Tumors

Elevated Placental Growth Factor Levels after Allogeneic Hematopoietic Cell Transplantation: Clinical and Peripheral Blood Mononuclear Cell Receptor Expression Correlates

The Contribution of Toll-like Receptor (TLR) Pathway Hyper-Reactivity to Clonal Selection in Secondary MDS and AML

Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only